डॉ. केनेथ पीटर्स कहते हैं, ‘मैं पोस्ट-ड्रग सिंड्रोम की तह तक जाने के लिए उत्साहित हूं’
20 मई, 2025
प्रिय मित्रों:
206 / 5,000
यदि आपने कभी इस बात पर शिकायत की है कि पीएफएस पर पर्याप्त शोध नहीं हो रहा है, तो आपको यह जानकर खुशी होगी कि केनेथ एम. पीटर्स, एम.डी., न केवल इससे सहमत हैं, बल्कि वे इस महामारी विज्ञान संबंधी अन्याय को ठीक करने के मिशन पर हैं।
“In my practice, I’m seeing an increasing number of patients suffering long-term consequences from medications they’ve previously used. These include finasteride, Accutane, and SSRIs like Prozac, Zoloft and Celexa,” the Chair of Urology at Oakland University William Beaumont School of Medicine (OUWB) tells us.
“Very little is known about how these drugs can produce such devastating effects, nor do we know how they can be resolved,” he adds.
“There’s a tremendous need for research into, and awareness of, these post-drug syndromes. I’m passionate about getting to the bottom of them.”
Phase I in Dr. Peters’ project is a study titled, Interconnected Post-Drug Syndromes: Investigating the Impact of Retinoids, SSRIs, and Finasteride on Health and Well-being.
That research is one and the same with an anonymous, HIPAA-compliant survey designed to better gauge the severity of the most common post-drug syndromes (PDS).
“Additionally, our goal is to increase awareness about post-drug syndromes and engage the medical community to work together to identify potential therapies,” says Dr. Peters, adding that he will seek to publish his findings in a peer-reviewed journal.
Details of Phase II of the project is under wraps at the moment. But we can tell you that it will involve not only formulating more—and more in-depth—studies, but identifying funding sources for those projects.
“Additionally, our goal is to increase awareness about post-drug syndromes and engage the medical community to work together to identify potential therapies,” says Dr. Peters, adding that he will seek to publish his findings in a peer-reviewed journal.
Details of Phase II of the project is under wraps at the moment. But we can tell you that it will involve not only formulating more—and more in-depth—studies, but identifying funding sources for those projects.
Meanwhile, we encourage all PFS patients to participate in the survey, and all health care providers to recommend that their PDS patients do the same.
Anyone 18 years of age or older who took, then discontinued, finasteride, Saw Palmetto, retinoids, SSRIs, SNRIs or TCAs can complete the survey, which takes about 30 minutes.
Please be aware, however, that the deadline for participation is June 30.
To begin the process, click here.
Finasteride was originally developed by Merck & Co., Inc., and first approved by the US Food and Drug Administration in 1993 as Proscar (5 mg, for enlarged prostate), and again in 1997, as Propecia (1 mg, for hair loss).
In June 2021, Merck spun off its Organon subsidiary as an independent public company (NYSE: OGN). Founded in the Netherlands in 1923, Organon bills itself as a “global health care company dedicated to making a world of difference for women, their families and the communities they care for.”
Among the Merck products Organon acquired in the deal were Proscar and Propecia. To report adverse events for either finasteride product, call the Organon Service Center at (844)674-3200, or email Service_Center@Organon.com.
Anyone living in the US who suffers from PFS should also report his or her symptoms to the US FDA. Anyone living outside the US who suffers from PFS should report his or her symptoms to the US FDA as well as to his or her local DRA, as directed on our Report Your Side Effects page.
If you or a loved one are suffering from PFS, and feeling depressed or unstable, please don’t hesitate to contact the PFS Foundation as soon as possible via our Patient Support hotline: social@pfsfoundation.org
Thank you.